PE20151860A1 - Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida y su uso como inhidores de la phd - Google Patents

Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida y su uso como inhidores de la phd

Info

Publication number
PE20151860A1
PE20151860A1 PE2015002062A PE2015002062A PE20151860A1 PE 20151860 A1 PE20151860 A1 PE 20151860A1 PE 2015002062 A PE2015002062 A PE 2015002062A PE 2015002062 A PE2015002062 A PE 2015002062A PE 20151860 A1 PE20151860 A1 PE 20151860A1
Authority
PE
Peru
Prior art keywords
pirazol
phd
nicotinamide
hydroxy
derivatives
Prior art date
Application number
PE2015002062A
Other languages
English (en)
Spanish (es)
Inventor
Jason W Brown
Melinda Davis
Anthony Ivetac
Benjamin Jones
Andre A Kiryanov
Jon Kuehler
Marion Lanier
Joanne Miura
Sean Murphy
Wang Xiaolun
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20151860A1 publication Critical patent/PE20151860A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
PE2015002062A 2013-03-29 2014-03-26 Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida y su uso como inhidores de la phd PE20151860A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361806806P 2013-03-29 2013-03-29
US201361916715P 2013-12-16 2013-12-16

Publications (1)

Publication Number Publication Date
PE20151860A1 true PE20151860A1 (es) 2015-12-16

Family

ID=50792544

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015002062A PE20151860A1 (es) 2013-03-29 2014-03-26 Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida y su uso como inhidores de la phd

Country Status (40)

Country Link
US (5) US9040522B2 (enExample)
EP (2) EP2978752B1 (enExample)
JP (4) JP6282724B2 (enExample)
KR (1) KR102376354B1 (enExample)
CN (1) CN105492433B (enExample)
AP (1) AP2015008783A0 (enExample)
AU (1) AU2014241183B2 (enExample)
BR (1) BR112015020350B1 (enExample)
CA (1) CA2903875C (enExample)
CL (1) CL2015002473A1 (enExample)
CR (1) CR20150517A (enExample)
CY (1) CY1120029T1 (enExample)
DK (1) DK2978752T3 (enExample)
EA (1) EA031647B1 (enExample)
EC (1) ECSP15045801A (enExample)
ES (1) ES2660914T3 (enExample)
GE (1) GEP201706761B (enExample)
HR (1) HRP20180341T1 (enExample)
HU (1) HUE038220T2 (enExample)
IL (1) IL240803B (enExample)
JO (1) JO3722B1 (enExample)
LT (1) LT2978752T (enExample)
ME (1) ME03024B (enExample)
MX (1) MX370388B (enExample)
MY (1) MY184218A (enExample)
PE (1) PE20151860A1 (enExample)
PH (1) PH12015502248B1 (enExample)
PL (1) PL2978752T3 (enExample)
PT (1) PT2978752T (enExample)
RS (1) RS56974B1 (enExample)
SG (1) SG11201506749XA (enExample)
SI (1) SI2978752T1 (enExample)
SM (1) SMT201800112T1 (enExample)
TN (1) TN2015000397A1 (enExample)
TR (1) TR201802632T4 (enExample)
TW (1) TWI635084B (enExample)
UA (1) UA118965C2 (enExample)
UY (1) UY35513A (enExample)
WO (1) WO2014160810A1 (enExample)
ZA (1) ZA201506484B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2978752T1 (en) * 2013-03-29 2018-04-30 Takeda Pharmaceutical Company Limited 6- (5-Hydroxy-1H-pyrazol-1-yl) nicotinamide derivatives and their use as inhibitors of PHD
SG10201902963PA (en) 2014-10-06 2019-05-30 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
GEP20217329B (en) 2016-09-30 2021-12-10 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
HUE052205T2 (hu) 2016-12-09 2021-04-28 Vertex Pharma Cisztás fibrózis transzmembrán vezetõképesség szabályzó modulátora, gyógyszerészeti készítmények, kezelési eljárások és eljárás a modulátor elõállítására
BR112019025801A2 (pt) 2017-06-08 2020-07-07 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
CN107163043A (zh) * 2017-06-16 2017-09-15 上海毕得医药科技有限公司 一种吡唑并[1,5‑a]吡啶‑3‑羧酸酯衍生物的合成方法
BR112020000941A2 (pt) 2017-07-17 2020-07-21 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
US11434201B2 (en) 2017-08-02 2022-09-06 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
CA3078893A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
CA3085006A1 (en) 2017-12-08 2019-06-13 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
JP7301042B2 (ja) 2018-03-30 2023-06-30 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除組成物
WO2019195739A1 (en) * 2018-04-05 2019-10-10 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CN111349077B (zh) * 2019-02-02 2022-06-28 杭州华东医药集团新药研究院有限公司 一种哒嗪衍生物及其制备方法和医药用途
IL296632A (en) * 2020-03-20 2022-11-01 Akebia Therapeutics Inc phd inhibitory compounds, compositions and use
EP4121424A1 (en) * 2020-03-20 2023-01-25 Akebia Therapeutics Inc. Phd inhibitor compounds, compositions, and their use
TW202140443A (zh) * 2020-03-20 2021-11-01 美商阿克比治療有限公司 Ｐｈｄ抑制劑化合物、組成物及使用方法
EP4138825A1 (en) 2020-04-20 2023-03-01 Akebia Therapeutics Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
TW202313072A (zh) 2021-05-27 2023-04-01 美商凱立克斯生物製藥股份有限公司 檸檬酸鐵之兒科調配物
JP7710897B2 (ja) * 2021-06-01 2025-07-22 三菱ガス化学ネクスト株式会社 １－アルキル－５－ヒドロキシピラゾールの製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663327A (en) 1984-05-23 1987-05-05 Bayer Aktiengesellschaft 1-heteroaryl-4-aryl-pyrazolin-5-ones
DE3443308A1 (de) 1984-11-28 1986-05-28 Bayer Ag, 5090 Leverkusen 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
US20040067955A1 (en) * 2002-09-06 2004-04-08 Fujisawa Pharmaceutical Co. Ltd. Pyridazinone compound and pharmaceutical use thereof
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
MX2008002063A (es) 2005-08-19 2008-04-16 Astrazeneca Ab Derivados de pirazolona para el tratamiento de tuberculosis.
PL3357911T3 (pl) * 2006-06-26 2022-09-05 Akebia Therapeutics Inc. Inhibitory prolilohydroksylazy i sposoby ich użycia
PT2090570E (pt) * 2006-09-05 2011-12-29 Kyowa Hakko Kirin Co Ltd Derivado de imidazole
DE102006050516A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
DE102006050515A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
DK2439205T3 (da) 2006-12-29 2015-06-22 Abbvie Deutschland Carboxamidforbindelser og deres anvendelse som calpaininhibitorer
DE102007044032A1 (de) 2007-09-14 2009-03-19 Bayer Healthcare Ag Substituierte heterocyclische Verbindungen und ihre Verwendung
ES2524883T3 (es) * 2008-03-18 2014-12-15 Merck Sharp & Dohme Corp. 4-Hidroxipirimidina-5-carboxamidas sustituidas
US8268834B2 (en) * 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
AU2009334570B2 (en) * 2008-12-29 2016-06-09 Sanofi Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof
EA019591B1 (ru) * 2008-12-29 2014-04-30 Санофи Производные 2-пиридин-2-ил-пиразол-3(2h)-она, их получение и применение в терапии в качестве активаторов hif
SI2978752T1 (en) * 2013-03-29 2018-04-30 Takeda Pharmaceutical Company Limited 6- (5-Hydroxy-1H-pyrazol-1-yl) nicotinamide derivatives and their use as inhibitors of PHD

Also Published As

Publication number Publication date
AU2014241183B2 (en) 2018-08-09
US20180186772A1 (en) 2018-07-05
BR112015020350A2 (pt) 2017-07-18
EA201591889A1 (ru) 2016-01-29
TN2015000397A1 (en) 2017-01-03
UA118965C2 (uk) 2019-04-10
IL240803A0 (en) 2015-10-29
CY1120029T1 (el) 2018-12-12
IL240803B (en) 2019-02-28
JP2016515582A (ja) 2016-05-30
SMT201800112T1 (it) 2018-05-02
EP3336084B1 (en) 2021-03-17
CL2015002473A1 (es) 2016-08-26
US20160251337A1 (en) 2016-09-01
PH12015502248A1 (en) 2016-02-01
JP6282724B2 (ja) 2018-02-21
JO3722B1 (ar) 2021-01-31
US9040522B2 (en) 2015-05-26
AP2015008783A0 (en) 2015-10-31
AU2014241183A1 (en) 2015-09-24
KR102376354B1 (ko) 2022-04-04
HK1217701A1 (en) 2017-01-20
PT2978752T (pt) 2018-03-09
HRP20180341T1 (hr) 2018-04-20
PL2978752T3 (pl) 2018-06-29
US20150224113A1 (en) 2015-08-13
JP6874114B2 (ja) 2021-05-19
EA031647B1 (ru) 2019-02-28
EP2978752A1 (en) 2016-02-03
ZA201506484B (en) 2017-11-29
UY35513A (es) 2014-10-31
CA2903875A1 (en) 2014-10-02
CA2903875C (en) 2021-07-20
HUE038220T2 (hu) 2018-10-29
SG11201506749XA (en) 2015-09-29
US20140296200A1 (en) 2014-10-02
US9708296B2 (en) 2017-07-18
CN105492433A (zh) 2016-04-13
MX370388B (es) 2019-12-11
TR201802632T4 (tr) 2018-03-21
BR112015020350B1 (pt) 2023-04-25
DK2978752T3 (en) 2018-03-12
CN105492433B (zh) 2018-11-23
JP2019069997A (ja) 2019-05-09
MY184218A (en) 2021-03-26
GEP201706761B (en) 2017-10-25
EP2978752B1 (en) 2017-11-29
ME03024B (me) 2018-10-20
PH12015502248B1 (en) 2016-02-01
US9944626B2 (en) 2018-04-17
EP3336084A1 (en) 2018-06-20
LT2978752T (lt) 2018-03-26
RS56974B1 (sr) 2018-05-31
JP2020073538A (ja) 2020-05-14
TW201446752A (zh) 2014-12-16
KR20150135794A (ko) 2015-12-03
ES2660914T3 (es) 2018-03-26
TWI635084B (zh) 2018-09-11
CR20150517A (es) 2016-01-12
SI2978752T1 (en) 2018-04-30
US9345713B2 (en) 2016-05-24
JP6462911B2 (ja) 2019-01-30
MX2015013687A (es) 2016-02-25
JP6640978B2 (ja) 2020-02-05
WO2014160810A1 (en) 2014-10-02
JP2018083838A (ja) 2018-05-31
US10407409B2 (en) 2019-09-10
NZ711522A (en) 2021-02-26
US20170275271A1 (en) 2017-09-28
ECSP15045801A (es) 2017-02-24

Similar Documents

Publication Publication Date Title
PE20151860A1 (es) Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida y su uso como inhidores de la phd
CY1124855T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
NI201600166A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso para tratar cáncer
MX2017004906A (es) Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma.
MX2015009950A (es) Compuestos de imidazopiridina y sus usos.
UY36244A (es) Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
UY34960A (es) Dihidropiridona p1 como inhibidores del factor xia
ECSP14004812A (es) Triazolopiridinas sustituidas
CO7131357A2 (es) Compuestos de n-ariltriazol como antagonistas de lpar
CO7131358A2 (es) Compuestos de n-alquiltriazol como antagonistas de lpar
MX2018000179A (es) Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
MX383686B (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
UY34974A (es) Piridazina 1,4 disustituida, análogos de la misma y métodos para tratar las enfermedades relacionadas con deficiencia del smn
PE20152033A1 (es) Heterociclos bicicliclos como inhibidores de fgfr
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
UY35972A (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
CO2017000438A2 (es) Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble
UY34959A (es) Dihidropiridona p1 como inhibidores del factor xia
DOP2017000278A (es) Piridinas sustituidas y método de uso
GT201300254A (es) Triazolopiridinas
CO7131360A2 (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
MX2020005738A (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
CO7160077A2 (es) Compuestos de pirazol sustituidos como antagonistas de lpar

Legal Events

Date Code Title Description
FG Grant, registration